aqueou
decoct
tradit
chines
medicin
ban
lan
gen
isati
indigotica
root
antivir
natur
product
ci
isol
nnrti
nonnucleosid
revers
transcriptas
inhibitor
ec
mm
novel
structur
determin
methyl
acetamidobenzo
spectroscop
data
confirm
singl
crystal
xray
diffract
synthesi
structureact
relationship
sar
investig
ci
new
deriv
ec
valu
mm
two
optim
deriv
ec
mm
mm
activ
compar
nvp
ec
mm
obtain
evalu
verifi
rt
dna
polymeras
inhibitor
exhibit
better
activ
drug
resist
fold
compar
nvp
seven
nnrtiresist
strain
carri
differ
mutat
especi
ec
mm
activ
doublemut
strain
compar
nvp
ec
mm
efv
ec
mm
molecular
dock
demonstr
possibl
bind
pattern
rt
reveal
activ
mechan
nnrtiresist
strain
chemic
shift
valu
measur
mhz
h
mhz
c
respect
proton
coupl
constant
j
hz
given
parenthes
assign
base
dept
h
cosi
hsqc
hmbc
experi
c
xu
et
al
acquir
immunodefici
syndrom
aid
caus
human
immunodefici
viru
hiv
infect
destroy
bodi
immun
system
infect
human
immun
cell
caus
patient
eventu
die
complic
sever
infect
secondari
tumor
approxim
million
peopl
worldwid
live
hivaid
includ
million
children
moreov
million
individu
becam
newli
infect
aid
vaccin
avail
highli
activ
antiretrovir
therapi
haart
still
main
clinic
treatment
hivaid
mani
haart
compris
two
three
antiretrovir
drug
act
differ
target
revers
transcriptas
rt
proteas
pr
integras
howev
longterm
widespread
use
haart
lead
drugresist
virus
treatment
failur
least
patient
drugresist
virus
nonnucleosid
revers
transcriptas
inhibitor
nnrti
nevirapin
nvp
efavirenz
efv
use
year
clinic
practic
stabl
drugresist
strain
emerg
clinic
studi
found
week
etravirin
rilpivirin
administr
bodi
produc
viru
resist
drug
sever
new
form
nnrti
report
recent
year
consider
drug
resist
continu
increas
develop
new
nnrti
still
worth
challeng
ban
lan
gen
isati
indigotica
root
one
import
tradit
chines
medicin
use
treatment
influenza
variou
infecti
diseas
well
antisever
acut
respiratori
syndrom
sar
previou
studi
demonstr
indirubin
one
bioactiv
indol
alkaloid
herbal
drug
signific
cytotox
cell
inhibitori
effect
pesudorabi
viru
prv
replic
extract
root
leav
indigotica
also
show
cytopath
effect
cpe
reduct
either
infect
prv
porcin
kidney
cell
moreov
ethanol
extract
da
qing
ye
indigotica
leav
isatisin
aderiv
artifici
acetonid
report
moder
activ
ec
mm
howev
far
know
neither
extract
purifi
compound
ban
lan
gen
report
inhibit
hiv
viru
replic
ban
lan
gen
decoct
practic
use
clinic
wherea
ethanol
extract
mainli
focus
previou
studi
systemat
studi
chemic
constitu
biolog
activ
aqueou
extract
indigotica
root
result
character
chemic
constitu
includ
around
alkaloid
antivir
influenza
viru
ahanfang
herp
simplex
viru
andor
coxsacki
viru
celldamag
protect
activ
continu
work
led
character
novel
antihiv
compound
methyl
acetamidobenzo
ci
fig
ec
valu
mm
remain
subfract
ci
repres
first
indolylacetamidobenzo
deriv
indigotica
though
plant
varieti
natur
product
extract
inhibit
replic
report
view
structur
ci
inhibitori
effect
viru
along
recent
report
indol
deriv
antihiv
activ
determin
optim
activ
physicochem
properti
synthesi
obtain
optim
lead
compound
drug
candid
worthi
studi
limit
sampl
amount
plant
extract
ci
firstli
synthes
confirm
replic
structur
optim
effect
follow
structur
chang
activ
investig
studi
shift
methoxyformyl
phenylamin
moieti
replac
introduct
function
group
ii
replac
phenyl
ring
aromat
heterocycl
ring
iii
substitut
nmethoxi
group
indol
nucleu
nalkoxi
group
iv
extens
shorten
acetamid
linker
indol
phenyl
ring
unit
synthet
lead
compound
ci
potent
deriv
test
activ
strain
carri
clinic
relev
mutat
confer
resist
nnrti
herein
report
isol
structur
determin
synthesi
lead
compound
ci
along
synthesi
activ
structureact
relationship
new
deriv
well
activ
three
optim
compound
novel
nnrti
seven
nnrtiresist
strain
carri
differ
rtmutat
molecular
dock
lead
compound
ci
potent
compound
also
discuss
chemistri
isol
structur
elucid
antivir
assay
ci
aqueou
decoct
airdri
pulvar
indigotica
root
concentr
reduc
pressur
separ
column
chromatographi
cc
macropor
adsorb
resin
elut
success
h
etoh
etoh
yield
three
correspond
fraction
b
c
fraction
c
subject
cc
silica
gel
elut
use
gradient
increas
aceton
concentr
petroleum
ether
afford
fraction
fraction
separ
success
cc
sephadex
revers
phase
silica
gel
c
silica
gel
give
mixtur
ci
isol
hplc
use
semiprepar
column
see
experiment
section
compound
ci
obtain
colorless
prism
aceton
ir
spectrum
show
presenc
amino
cm
ester
amid
carbonyl
cm
aromat
ring
cm
function
molecul
combinatori
analysi
hrm
nmr
spectroscop
data
led
determin
molecular
formula
c
h
n
molecular
occurr
indol
nucleu
orthosubstitut
benzen
ring
two
methoxi
group
isol
methylen
two
ester
amid
carbonyl
carbon
deduc
analysi
nmr
spectroscop
data
tabl
connect
structur
unit
establish
nmr
experiment
data
illustr
fig
briefli
linkag
indol
nucleu
one
carbonyl
carbon
via
methylen
unit
form
acetyl
moieti
unambigu
h
cosi
spectrum
well
twoand
threebond
heteronuclear
correl
h
hmbc
spectrum
along
chemic
shift
proton
carbon
signal
fig
locat
methoxyformyl
orthosubstitut
benzen
ring
construct
methyl
orthosubstitut
benzoat
moieti
deduc
h
cosi
coupl
correl
longrang
hmbc
correl
well
och
satisfi
requir
molecular
composit
remain
methoxi
unit
must
locat
n
atom
acetyl
moieti
turn
must
link
via
amid
bond
open
posit
methyl
orthosubstitut
benzoat
moieti
deduct
final
prove
xray
diffract
analysi
suitabl
singl
crystal
crystal
aceton
solut
ci
ortep
drawn
crystal
structur
shown
fig
thu
structur
ci
determin
methyl
acetamidobenzo
accord
clinic
applic
ban
lan
gen
indigotica
root
tradit
chines
medicin
antivir
activ
ci
assay
use
cellbas
protocol
report
previou
public
synthesi
ci
shown
scheme
methyl
acetamido
benzoat
cia
obtain
amid
reaction
acid
methyl
acetamido
benzoat
cib
prepar
reduct
use
trifluoroacet
acid
triethylsilan
oxid
cib
carri
sodium
tungstat
hydrogen
peroxid
produc
methyl
acetamido
benzoat
cic
methyl
cic
trimethylsilyldiazomethan
produc
ci
synthes
ci
inhibitori
activ
rt
rnadepend
dna
polymeras
ribonucleas
h
detect
along
activ
test
replic
result
tabl
indic
ci
inhibitor
rt
rnadepend
dna
polymeras
ic
valu
mm
inact
ribonucleas
h
ic
mm
synthesi
nalkoxi
indol
deriv
shown
scheme
first
two
step
obtain
intermedi
method
prepar
cia
cib
oxid
carri
mcpba
produc
indol
nhydroxyl
deriv
methyl
trimethylsilyldiazomethan
produc
target
product
synthes
presenc
potassium
carbon
halogen
alkan
intermedi
transform
indol
nhydroxyl
deriv
oxid
reaction
use
sodium
tungstat
hydrogen
peroxid
alkyl
basic
condit
provid
scheme
synthesi
depict
scheme
intermedi
prepar
sequenti
oxid
alkyl
result
product
reaction
oxalyl
chlorid
yield
transform
reduct
sodium
borohydrid
reaction
indol
pyridinecarboxaldehyd
basic
condit
afford
sequenti
reduc
oxid
yield
intermedi
via
propyl
synthes
scheme
synthes
ci
deriv
test
replic
wildtyp
viru
cytotox
hek
cell
well
shown
tabl
replac
either
neom
ci
neh
cia
neoh
cic
indol
indolin
cib
result
loss
activ
indic
nsubstitut
indol
moieti
one
key
pharmacophor
among
phenylamin
ring
substitut
deriv
orthohalogen
atom
cl
br
retain
activ
ec
valu
mm
respect
wherea
other
well
acetyl
linker
replac
propionyl
butyryl
result
loss
activ
accordingli
orthosubstitut
phenylamin
moieti
electronwithdraw
group
coom
cl
br
retent
acetyl
linker
essenti
maintain
activ
nalkoxysubstitut
deriv
ci
activ
decreas
prolong
linear
alkyl
chain
howev
halogen
analogu
activ
enhanc
extend
linear
alkyl
chain
one
five
carbon
atom
eg
methoxi
ec
carbon
atom
exceed
six
viru
replic
inhibit
gradual
decreas
ec
mm
ec
mm
ec
mm
complet
lost
carbon
atom
number
reach
addit
introduct
bulki
unit
natom
indol
moieti
also
weaken
activ
eg
benzyloxi
ec
mm
phenethyloxi
ec
mm
pmethoxybenzyloxi
complet
loss
activ
observ
also
electronwithdraw
acetyloxi
benzyloxi
substitut
natom
indol
moieti
interestingli
compar
ec
mm
potenc
decreas
orthosubstitut
electronwithdraw
group
cf
phenylamin
moieti
ec
mm
differ
aforement
result
indic
nalkoxi
ci
deriv
requir
activ
viru
replic
best
activ
gain
number
linear
alkyl
carbon
atom
three
ec
mm
replac
phenylamin
moieti
pyridinamin
activ
retain
deriv
ec
replac
methylen
unit
result
disappear
activ
therefor
synthes
deriv
moieti
optim
replac
methyl
moieti
natur
product
ci
three
potent
compound
select
follow
investig
notabl
discov
intermedi
inact
highlyselect
tyrosin
kinas
inhibitor
myeloprolif
neoplasm
deriv
inact
mm
shown
tabl
compound
cytotox
test
cell
viabil
influenc
somehow
treat
compound
maximum
concentr
mm
nevertheless
cc
compound
higher
mm
highest
concentr
antihiv
replic
assay
timeofdrug
addit
toa
assay
conduct
identifi
stage
activ
compound
inhibitori
effect
revers
transcriptas
inhibitor
zidovudin
azt
efv
integras
inhibitor
raltegravir
ral
use
refer
drug
assay
show
activ
lost
curv
close
azt
efv
rang
time
failur
ft
h
compar
azt
h
efv
h
far
ahead
integras
inhibitor
ral
ft
h
fig
indic
compound
inhibit
replic
revers
transcript
step
revers
transcript
process
gener
doublestrand
provir
dna
rna
genom
templat
complex
process
preceed
rt
catalysi
dna
polymeras
ribonucleas
h
activ
dna
strand
gener
dna
polymeras
activ
base
templat
rna
templat
rna
hydrolyz
ribonucleas
h
sinc
lead
compound
ci
prove
rt
dna
polymeras
inhibitor
also
test
effect
compound
rt
dna
polymeras
ribonucleas
h
activ
shown
tabl
three
compound
display
inhibitori
activ
rt
rnadepend
dna
polymeras
ribonucleas
h
indic
compound
rt
dna
polymeras
inhibitor
rt
compris
two
subunit
catalyt
subunit
design
finger
palm
thumb
connect
rnase
h
domain
member
approv
nnrti
rtdna
polymeras
inhibitor
bind
hydrophob
pocket
locat
base
thumb
bsheet
palm
domain
catalyt
activ
center
due
low
fidel
replic
two
decad
nnrti
use
clinic
nnrtiresist
mutant
develop
among
carri
rt
preval
mutant
locat
outer
rim
nnrtibind
pocket
vicin
entranc
pocket
locat
nnrtibind
pocket
chang
asparagin
rt
catalyt
pocket
prefer
close
form
result
less
electrostat
forc
within
nnrti
exist
catalyt
pocket
nnrti
act
pp
interact
aromat
ring
mutat
occur
forc
nnrti
rt
pp
interact
disappear
novel
nnrti
activ
exist
nnrtiresist
pivot
characterist
studi
evalu
activ
natur
product
ci
potent
deriv
replic
seven
nnrtiresist
strain
overal
exhibit
better
activ
drug
resist
fold
compar
nvp
six
seven
resist
strain
tabl
particularli
ec
mm
notabl
activ
doubl
mutant
compar
nvp
ec
mm
efv
ec
mm
worth
note
natur
product
ci
one
fulli
activ
viral
mutant
though
exhibit
best
activ
among
four
test
compound
scheme
synthesi
target
compound
reagent
condit
naoh
meoh
rt
b
et
sih
cf
cooh
reflux
c
sodium
tungstat
dihydr
hydrogen
peroxid
meoh
c
c
k
co
dmf
rt
effect
compound
wild
type
replic
order
better
understand
possibl
bind
mode
activ
compound
potent
ci
well
posit
control
nvp
efv
dock
wt
rt
pdb
code
rt
mutant
pdb
code
pdb
code
pdb
code
respect
dock
result
wt
rt
fig
show
palkyl
interact
indol
ring
ii
alkyl
interact
end
butoxi
chain
respect
addit
hbond
oxygengermin
hydrogen
nalkoxi
chain
carbonyl
oxygen
iii
pp
interact
pyridin
ring
respect
iv
interact
chlorin
residu
dock
mutat
rt
fig
indic
interact
chlorin
wt
rt
replac
palkyl
interact
pyridin
ring
retain
pp
interact
pyridin
ring
addit
pyridin
ring
lost
act
forc
turn
psigma
interact
indol
ring
differ
dock
result
ci
show
termin
methyl
group
methoxyformyl
phenylamin
moieti
share
palkyl
interact
alkyl
interact
fig
support
inform
compound
dock
doublemut
rt
fig
show
hbond
form
amid
nh
group
nalkoxi
oxygen
atom
replac
palkyl
interact
indol
ring
wt
rt
meanwhil
pp
interact
pyridin
ring
substitut
psulfur
interact
indol
nucleu
esh
group
addit
pyridin
n
atom
hydrogenbond
phenol
hydroxi
proton
termin
enh
pyridin
ring
maintain
pp
interact
howev
carbonyl
oxygen
methoxyformyl
phenylamin
moieti
ci
hydrogenbond
termin
enh
phenol
hydroxi
proton
maintain
mode
action
fig
support
inform
posit
control
nvp
resist
doublemut
rt
dock
simul
fig
support
inform
show
interact
nvp
suggest
hbond
nalkoxi
oxygen
atom
amid
nh
group
may
play
import
role
effect
support
experiment
data
tabl
case
doublemut
rt
figur
dock
exhibit
posit
exchang
indol
pyridin
ring
moieti
interact
model
hydroxi
group
isomer
acetamid
unit
tabl
repres
exhibit
much
better
inhibitori
effect
six
seven
test
resist
strain
compar
nvp
moreov
two
candid
strongli
suppress
nnrtiresist
carri
mutat
especi
superior
nvp
efv
suggest
potenti
use
develop
new
nnrti
addit
comput
dock
result
also
hint
possibl
bind
mechan
potent
summari
class
deriv
good
antivir
prospect
deserv
investig
gener
experiment
procedur
plant
materi
extract
preliminari
fraction
extract
see
ref
fraction
g
subject
cc
sephadex
chcl
meoh
give
g
fraction
rp
flash
cc
meoh
h
give
fraction
subfract
mg
separ
cc
silica
gel
elut
gradient
increas
meoh
chcl
afford
mg
isol
revers
phase
hplc
use
semiprepar
column
mobil
phase
meoh
h
yield
ci
mg
synthet
start
materi
reagent
purchas
commerci
supplier
use
directli
without
purif
column
chromatographi
perform
use
silica
gel
mesh
purchas
qingdao
haiyang
chemic
co
ltd
thinlay
chromatographi
perform
precoat
silica
gel
plate
visual
uv
light
nmr
nmr
spectra
record
varian
mercuri
mhz
mhz
mhz
tm
solvent
peak
refer
chemic
shift
report
part
per
million
ppm
coupl
constant
j
report
hertz
hz
split
pattern
indic
singlet
doublet
triplet
q
quartet
dd
doublet
doublet
multiplet
hresim
data
obtain
agil
accuratemass
qtof
lcm
spectromet
agil
technolog
ltd
santa
clara
ca
usa
analysi
sampl
puriti
perform
agil
hplc
system
consist
control
pump
dual
l
absorb
detector
capcel
pak
column
solut
acid
g
equiv
dri
ch
cl
ml
ad
edci
g
equiv
reaction
mixtur
stir
room
temperatur
h
methyl
g
equiv
dmap
g
equiv
ad
mixtur
stir
room
temperatur
h
hydrochlor
acid
ml
ad
stir
strongli
min
organ
phase
separ
water
phase
extract
ch
cl
ml
twice
combin
organ
phase
wash
brine
dri
na
filtrat
remov
solvent
c
reduc
pressur
yield
methyl
acetamido
benzoat
cia
g
solut
cia
g
equiv
cf
cooh
ml
ad
et
sih
g
equiv
stir
c
h
follow
recoveri
solvent
reduc
pressur
yield
residu
residu
dissolv
ethyl
acet
wash
satur
na
co
brine
order
subsequ
remov
solvent
reduc
pressur
afford
methyl
acetamido
benzoat
cib
g
solut
cib
g
equiv
meoh
ml
ad
sodium
tungstat
dehydr
g
equiv
c
follow
dropwis
addit
hydrogen
peroxid
ml
equiv
stir
c
h
reaction
mixtur
partit
ch
cl
water
organ
phase
wash
brine
evapor
result
residu
purifi
column
chromatographi
silica
gel
petroleum
etherethyl
acet
furnish
methyl
acetamido
benzoat
cic
g
select
ch
cl
solut
cic
g
ad
solut
trimethylsilyldiazomethan
nhexan
ml
equiv
stir
room
temperatur
overnight
follow
recoveri
organ
solvent
give
residu
residu
purifi
silica
gel
column
chromatographi
petroleum
etherethyl
acet
yield
ci
gener
procedur
synthesi
first
two
step
gener
procedur
synthesi
intermedi
prepar
cia
cib
solut
equiv
meoh
ad
mcpba
equiv
stir
room
temperatur
h
concentr
reduc
pressur
yield
residu
dissolv
ch
cl
wash
success
satur
na
co
brine
ch
cl
solut
evapor
result
residu
purifi
column
chromatographi
silica
gel
petroleum
etherethyl
acet
furnish
similarli
obtain
procedur
prepar
cic
select
ch
cl
solut
ad
solut
trimethylsilyldiazomethan
nhexan
equiv
alkyl
halid
equiv
stir
room
temperatur
overnight
h
dmf
k
co
equiv
follow
partit
ch
cl
water
dri
na
recoveri
organ
solvent
give
residu
residu
purifi
silica
gel
column
chromatographi
petroleum
ether
ethyl
acet
yield
four
step
yield
cold
solut
meoh
c
ad
sodium
tungstat
dehydr
equiv
dropwis
hydrogen
peroxid
equiv
stir
c
h
ad
ch
cl
water
stir
min
separ
wash
brine
dri
anhydr
na
organ
phase
evapor
give
residu
ad
dmf
k
co
equiv
alkyl
halid
equiv
stir
room
temperatur
h
follow
addit
water
ethyl
acet
stir
min
organ
layer
separ
dri
anhydr
na
evapor
give
residu
residu
dissolv
diethyl
ether
ad
oxalyl
chlorid
equiv
dropwis
c
stir
room
temperatur
h
remov
diethyl
ether
redissolv
ch
cl
solut
ad
equiv
triethylamin
equiv
dropwis
c
stir
room
temperatur
h
evapor
solvent
gave
residu
purifi
silica
gel
column
chromatographi
petroleum
etherethyl
acet
furnish
solut
equiv
methanol
ad
sodium
borohydrid
equiv
stir
h
dilut
water
extract
ethyl
acet
ethyl
acet
layer
wash
brine
evapor
afford
residu
purifi
silica
gel
column
chromatographi
petroleum
etherethyl
acet
obtain
n
acetamid
three
step
yield
h
nmr
vsvg
plasmid
envdefici
hiv
vector
contain
luciferas
report
eor
e
rtmutant
cotransfect
hek
cell
h
post
transfect
supernat
collect
filter
mm
filter
harvest
rtmutant
virion
quantifi
use
elisa
kit
zeptometrix
cat
hek
cell
seed
plate
densiti
cellswel
one
day
prior
infect
test
compound
ad
well
min
ahead
rtmutant
infect
ng
infect
cell
lyse
h
postinfect
luciferas
activ
measur
use
siriu
luminomet
berthold
detect
system
accord
manufactur
instruct
infect
luciferas
activ
test
compound
luciferas
activ
dmso
hek
cell
cellswel
plate
treat
compound
indic
concentr
h
cell
viabil
measur
assay
promega
madison
wi
usa
accord
manufactur
protocol
cell
treat
amount
dmso
serv
solvent
control
cell
viabil
test
compound
calcul
cell
viabil
rlu
test
compound
rlu
dmso
revers
transcriptas
rnadepend
dna
polymeras
activ
detect
describ
previous
test
compound
ad
ml
reaction
system
contain
mgml
poli
ra
mgml
oligo
dt
mm
dttp
nm
nm
mm
trishcl
ph
mm
kcl
mm
mgcl
mm
dtt
reaction
initi
rt
addit
blank
control
conduct
without
ad
rt
solvent
control
add
dmso
instead
test
compound
mixtur
incub
c
h
follow
transfer
streptavidinco
plate
roch
h
incub
c
supernat
discard
plate
wash
pb
antidigpod
ad
plate
incub
c
h
plate
wash
tmb
ad
min
h
ad
termin
reaction
od
valu
read
multimod
reader
tecan
rnadepend
dna
polymeras
activ
test
compound
e
blank
control
solvent
control
e
blank
control
detect
ribonucleas
h
activ
perform
describ
previous
briefli
ml
test
compound
ad
ml
reaction
system
contain
mm
trishcl
ad
reaction
system
react
min
room
temperatur
blank
control
conduct
without
ad
rt
solvent
control
add
dmso
instead
test
compound
reaction
termin
ad
ml
edta
rel
fluoresc
unit
rfu
detect
multimod
reader
tecan
ex
nm
em
nm
ribonucleas
h
activ
rfu
test
compound
erfu
blank
control
rfu
solvent
control
erfu
blank
control
mean
valu
standard
deviat
sd
half
maxim
effect
concentr
ec
half
maxim
inhibitori
concentr
ic
cytotox
concentr
cc
calcul
graphpad
prism
softwar
molecular
dock
perform
discoveri
studio
client
softwar
packag
accelri
san
diego
usa
complex
structur
obtain
protein
data
bank
wt
rt
rt
doublemut
rt
doublemut
rt
complex
water
molecul
origin
ligand
remov
bind
caviti
activ
site
redock
compound
test
structur
receptor
ligand
dock
energi
optim
dock
carri
cdocker
protocol
employ
charmm
calcul
perform
dell
optiplex
workstat
author
declar
known
compet
financi
interest
person
relationship
could
appear
influenc
work
report
paper
